Serimmune, Merck reach drug discovery milestone

By The Science Advisory Board staff writers

April 3, 2020 -- Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.

The collaboration included Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to help identify antigens that stimulate immunity. The goal is to develop and commercialize promising agents.

Serimmune can receive payments related to research, development, and regulatory milestones as well as tiered royalty payments on sales arising from products that result from the partnership, the company noted.

Merck to build new biotech R&D center in Switzerland
Merck announced on January 27 an investment of 250 million euros ($275 million) to build a new biotech R&D center in Corsier-sur-Vevey, Switzerland.
Merck announces new drug development collaboration
Merck announced on January 6 that it has entered into an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter